Hospital-acquired infections are majorly caused by fungal, bacterial, and viral pathogens. Several cases of hospital infections are acquired from the intensive care units of hospitals. A huge number of antimicrobial drugs have demonstrated their capability in treating a wide range of hospital infections.

The increasing number of pipeline drug molecules in the hospital infection therapeutics market is one of the biggest opportunities for the growth of the market. In addition, the absence of skilled staff in developing and underdeveloped countries and growing prevalence of several hospital infections are the major factors expected to fuel the growth of the market in the next few years.

Avail a Free Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280

Based on the major prominent types of drugs in the market, the global market for hospital infection therapeutics has been segmented into antiviral, antibacterial, and antifungal drugs. In 2013, the antibacterial drugs segment dominated the market, accounting for a 70.7% share in the global market for hospital infection therapeutics. This segment is projected to grow at a fast pace in the next few years. The research study has further analyzed the major drugs in the pipeline, including Plazomicin, Ceftolozane, Delafloxacin, Eravacycline, Surotomycin, Tedizolid, Amikacin Inhale, MK-3415A, CAZ AVI, Dalvance, and Oritavancin.

On the basis of type of infection, the global market for hospital infection therapeutics has been categorized into gastrointestinal disorders, hospital-acquired pneumonia, urinary tract infections, surgical site infections, bloodstream infections, and other infections. In 2013, the hospital-acquired pneumonia segment accounted for a 20% share in the global market for hospital infection therapeutics. Nevertheless, the urinary tract infections segment is anticipated to grow rapidly in the near future.

Currently, North America leads the overall market and is estimated to remain in the leading position in the next few years. North America is closely trailed by Europe. The rapid growth of these two regional markets can be attributed to the increasing healthcare awareness and growing demand for advanced drugs. On the other hand, the Asia Pacific market for hospital infection therapeutics is estimated to witness the fastest growth throughout the forecast period.

Furthermore, the research report talks about the competitive scenario of the global market for hospital infection therapeutics. Detailed profiles of the prominent players have been discussed in the scope of the research study. Some of the leading players operating in the market are Bayer AG, Johnson & Johnson Services, Inc., Actavis plc, Sanofi, Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc.

Browse Full Research Report: http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.